Page 110 - Read Online

Bile acid activates the JNK pathway and FXR, which suppresses 2006;66:11851-8.
cholesterol-7α-hydroxylase (CYP7A1), independently. Bile 4. Borgia G, Gentile I. Treating chronic hepatitis B: today and tomorrow.
[8]
acids are known to inhibit CYP7A1 gene transcription via direct 5. Curr Med Chem 2006;13:2839-55.
Gilbert S, Galarneau L, Lamontagne A, Roy S, Bélanger L. The hepatitis
activation of the JNK pathway, and FXR activates the JNK pathway B virus core promoter is strongly activated by the liver nuclear receptor
to suppress CYP7A1 in hepatocytes via inducing intestinal fetoprotein transcription factor or by ectopically expressed steroidogenic
fibroblast growth factor 15/19. In this study, JNK activation factor 1. J Virol 2000;74:5032-9.
affected FXR transcriptional activity and FXR protein levels but 6. Nakamura K, Hatano E, Narita M, Miyagawa-Hayashino A, Koyama Y,
Nagata H, Iwaisako K, Taura K, Uemoto S. Sorafenib attenuates
not FXR mRNA levels, suggesting that the JNK pathway may monocrotaline-induced sinusoidal obstruction syndrome in rats through
regulate FXR transcriptional activity and protein stability. suppression of JNK and MMP-9. J Hepatol 2012;57:1037-43.
7. Srisuttee R, Koh SS, Malilas W, Moon J, Cho IR, Jhun BH, Horio Y,
Chung YH. SIRT1 sensitizes hepatocellular carcinoma cells expressing
Sorafenib is a well-known Raf kinase inhibitor, but it also inhibits hepatitis B virus X protein to oxidative stress-induced apoptosis.
other kinases. The JNK pathway is one of the signaling pathways Biochem Biophys Res Commun 2012;429:45-50.
[13]
inhibited by sorafenib. However, sorafenib has been reported to 8. Li T, Jahan A, Chiang JY. Bile acids and cytokines inhibit the human
activate the JNK pathway to induce apoptosis. It seems to be in cholesterol 7 alpha-hydroxylase gene via the JNK/c-jun pathway in
[14]
conflict with each other, but the effect of sorafenib in a nontoxic 9. human liver cells. Hepatology 2006;43:1202-10.
Fung J, Lai CL, Seto WK, Yuen MF. Nucleoside/nucleotide analogues
concentration was confirmed in this study. Therefore, it may be in the treatment of chronic hepatitis B. J Antimicrob Chemother
important to use a proper dose of sorafenib to treat CHB. In 2011;66:2715-25.
this study, the proper dose of sorafenib was < 10 μmol/L. In 10. Pramoolsinsup C. Management of viral hepatitis B. J Gastroenterol
Hepatol 2002;17 Suppl: S125-45.
the other case, the proper dose of sorafenib that inhibits human 11. Terrault NA. Benefi ts and risks of combination therapy for hepatitis B.
cytomegalovirus replication and hepatitis C virus was below Hepatology 2009;49:S122-8.
2.5 and 15 μmol/L in vitro, respectively. [15,16] 12. Xie B, Wang DH, Spechler SJ. Sorafenib for treatment of hepatocellular
carcinoma: a systematic review. Dig Dis Sci 2012;57:1122-9.
13. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE,
In conclusion, these findings suggest that sorafenib, the Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R,
multi-kinase inhibitor, has an anti-viral effect on HBV gene Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G,
expression. Further research about the efficacy of targeting Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP. A quantitative analysis
the molecular signaling pathway of HBV replication should of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-32.
be evaluated for the treatment of CHB patients. 14. Rahmani M, Davis EM, Crabtree TR, Habibi JR, Nguyen TK, Dent P,
Grant S. The kinase inhibitor sorafenib induces cell death through
a process involving induction of endoplasmic reticulum stress.
ACKNOWLEDGMENTS Mol Cell Biol 2007;27:5499-513.
15. Michaelis M, Paulus C, Löschmann N, Dauth S, Stange E, Doerr HW,
Nevels M, Cinatl J Jr. The multi-targeted kinase inhibitor sorafenib
This work was supported by a 2-Year Research Grant of Pusan inhibits human cytomegalovirus replication. Cell Mol Life Sci
National University. 2011;68:1079-90.
16. Himmelsbach K, Sauter D, Baumert TF, Ludwig L, Blum HE, Hildt E.
REFERENCES New aspects of an anti-tumour drug: sorafenib effi ciently inhibits HCV
replication. Gut 2009;58:1644-53.
1. Kao JH, Chen DS. Global control of hepatitis B virus infection.
Lancet Infect Dis 2002;2:395-403. How to cite this article: Cho HK, Kim JR, Kim SY, Kyaw YY, Win AA,
Cheong JH. Sorafenib suppresses hepatitis B virus gene expression via
2. Liang TJ. Hepatitis B: the virus and disease. Hepatology 2009;49:S13-21. inhibiting JNK pathway. Hepatoma Res 2015;1:97-103.
3. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S,
Lynch M, Carter C. Sorafenib blocks the RAF/MEK/ERK pathway,
inhibits tumor angiogenesis, and induces tumor cell apoptosis Source of Support: This work was supported by a 2-Year Research Grant
of Pusan National University. Confl ict of Interest: None declared.
in hepatocellular carcinoma model PLC/PRF/5. Cancer Res

Hepatoma Research | Volume 1 | Issue 2 | July 15, 2015 103